Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07357519 · ClinicalTrials.gov registry record · Phase 1
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
A Phase 1 study of Relapsed / Refractory Osteosarcoma, sponsored by Lantheus Medical Imaging.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT07357519: Recruiting Phase 1 study of Relapsed / Refractory Osteosarcoma, sponsored by Lantheus Medical Imaging.
NCT07357519 is a Phase 1 study of Relapsed / Refractory Osteosarcoma that is actively recruiting participants, run by Lantheus Medical Imaging. The registered enrollment target is 55 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07357519, a Phase 1 study of Relapsed / Refractory Osteosarcoma, is actively recruiting participants, sponsored by Lantheus Medical Imaging.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
Primary Outcome
Incidence of DLTs during the first 8 weeks (DLT evaluation window) after the first dose of LNTH-2403
Conditions Studied
Interventions
- DRUG LNTH2403 Phase 1 dose
- DRUG Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2026-02 |
| Est. Completion | 2032-05 |
| Phase | Phase 1 |
What NCT07357519 shows while recruiting
NCT07357519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Relapsed / Refractory Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which LNTH2403 Phase 1 dose is the first listed.
NCT07357519 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07357519 about?
NCT07357519 is a clinical study titled "Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)". This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
What is the current status of trial NCT07357519?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2026-02. Estimated completion is 2032-05.
What conditions does trial NCT07357519 study?
This clinical trial studies the following conditions: Relapsed / Refractory Osteosarcoma.
What interventions are being tested in trial NCT07357519?
The interventions under investigation include: LNTH2403 Phase 1 dose (DRUG), Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). (DRUG).
Who is sponsoring clinical trial NCT07357519?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07357519 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07357519's enrollment target sits among peer trials
55 919th of 2000 higher than 1,070 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia